Successful Treatment of Transplant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defibrotide

Area of Science:

• Hematology
• Transplantation Medicine
• Vascular Biology

Background:

• Transplant-associated microangiopathy (TA-TMA) is a critical complication following stem cell transplantation.
• Standard management, including calcineurin/mTOR inhibitor withdrawal, is often insufficient.
• The unique pathophysiology of TA-TMA necessitates alternative therapeutic strategies.

Purpose of the Study:

• To evaluate the safety and efficacy of low-dose defibrotide in managing TA-TMA.
• To explore a cost-effective and accessible treatment option for TA-TMA, particularly in low and middle-income countries (LMICs).

Main Methods:

• A case series approach was employed to assess the outcomes of low-dose defibrotide administration.
• Treatment involved carefully monitored administration of defibrotide at reduced dosages.

Main Results:

• Low-dose defibrotide was administered safely and successfully in the studied cases.
• This approach demonstrated positive therapeutic responses in patients with TA-TMA.

Conclusions:

• Low-dose defibrotide presents a viable and effective therapeutic option for TA-TMA.
• This strategy is particularly relevant for LMICs due to financial considerations and warrants further prospective investigation.